Genomic testing and clinical decision making in CLL-
These videos are from European CLL experts intended for medical professionals and presented at or connected with the ERIC 2022 Meeting- using Med-Speak.
vjhemonc.com/feature/the-im...
Advances in the understanding of the CLL genome has led to the use of genomic and molecular biomarkers such as TP53 genetic alterations and immunoglobulin heavy variable (IgHV) gene mutation status. Hear more below from leading experts in CLL on the importance of genomic testing, and the impact of these results on diagnosis, prognosis and guiding treatment decisions.
-
How is high-risk disease defined in CLL?
In this new video from the recent ERIC 2022 Meeting, Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, reviews the significance of TP53 aberrations in defining high-risk disease in CLL. 6 Oct 2022
-
Kostas Stamatopoulos, MD, PhD, Center for Research and Technology Hellas, Thessaloniki, Greece, explains that patients with TP53 aberration and unmutated IgHV are considered high-risk when chemo-immunotherapy is the only treatment option; however, in the age of novel agents, the definition of high-risk CLL is changing. 13 Apr 2022
-
Why is it important to perform testing in CLL?
In this new video from the recent ERIC 2022 Meeting, Antonio Cuneo, MD, St. Anna University Hospital, Ferrera, Italy, highlights the importance of genomic testing prior to treatment initiation in CLL, and how testing informs treatment decisions. 7 Oct 2022
-
Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, highlights the importance of genomic tests such as fluorescence in situ hybridization (FISH) analysis, TP53 mutation screening and testing of IgHV mutational status to inform treatment decisions in patients with CLL. 13 Apr 2022
-
NEW PODCAST! vjhemonc.podbean.com/e/the-...
Prefer to listen? In this podcast, you will hear from Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, and Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, who discuss the importance of genomic testing in CLL and how this impacts treatment decisions.
-
What is the importance of re-testing in CLL?
In this new video from the recent ERIC 2022 Meeting, Barbara Eichhorst, MD, University Hospital Cologne, Germany, discusses the importance of re-testing patients with CLL after relapse. 7 Oct 2022
-
Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, discusses some of the key tests performed pre-treatment in patients with CLL, and that after relapse or disease progression, both FISH and TP53 analysis must be performed again to improve subsequent lines of treatment. 13 Apr 2022
-
Challenges in interpreting the results of genomic testing in CLL
In this new video from the recent ERIC 2022 Meeting, Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, comments on the challenges of interpreting the results of genomic tests in chronic lymphocytic leukemia (CLL), highlighting the need for quality control, particularly with next-generation sequencing (NGS) methods. 7 Oct 2022
-
Len
